RDC-0313 (ALKS 33) + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Binge Eating Disorder
Conditions
Binge Eating Disorder
Trial Timeline
May 1, 2010 → Jun 1, 2011
NCT ID
NCT01098435About RDC-0313 (ALKS 33) + Placebo
RDC-0313 (ALKS 33) + Placebo is a phase 2 stage product being developed by Alkermes for Binge Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01098435. Target conditions include Binge Eating Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01098435 | Phase 2 | Completed |
Competing Products
11 competing products in Binge Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Zonegran + sugar pill | Eisai | Phase 3 | 77 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| dasotraline 4mg + dasotraline 6mg + Placebo | Sumitomo Pharma | Phase 3 | 77 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol + Placebo | Jazz Pharmaceuticals | Approved | 82 |
| Sodium Oxybate | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |